<DOC>
	<DOCNO>NCT02680457</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( T2DM ) characterize wide fluctuation glucose . The long-acting insulin show improve glycemic variability however behavior insulin glargine versus insulin degludec unknown .</brief_summary>
	<brief_title>Effect Insulin Degludec Versus Insulin Glargine Glycemic Variability Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Clinical trial , crossover , double dommy , randomize , parallel group carry . The sample size calculate use formula clinical trial mean difference `` n '' 6 patient per group obtain . Patients 30 65 year age include T2DM , without hiperglycemic drug , A1C 6.5 11.0 % write signature consent . They assign randomly seal envelope either received insulin Degludec insulinGlargine ( 10 IU SC every 24 hour six day ) , patient administer initially insulin Degludec correspond insulin Glargine vice versa , washout period 14 day intervention . The clinical finding laboratory test include metabolic profile biosafety , make baseline . Body weight , body fat , body mass index blood pressure perform initial visit , likewise , interstitial glucose concentration ambulatory continuous glucose monitoring system ( Guardian® , Medtronic MiniMed , Northridge ) , mean amplitude glucose excursion [ MAGE ] area curve glucose calculate , serve assess glycemic variability . Adverse event adherence treatment document . Statistical analysis : Mann-Whitney U test , Wilcoxon , Chi2 , Fisher exact test . It consider significance p &lt; 0.05 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 2 diabetes mellitus without treatment least 3 month BMI 25.034.9 kg/m2 Diagnosis T2DM Fasting plasma glucose ≤300 mg/dL time scrutiny A1C 6.5 11 % Written inform consent Women pregnant breastfeeding Untreated thyroid disease and/or uncontrolled hypertension [ ≥150 systolic diastolic ≥90 ] Consumption oral agent medication supplement proven property modify behavior glucose . In case antihypertensive , may include treatment modify previous 3 month change study . Total cholesterol &gt; 240 mg/dL Triglycerides ≥400 mg/dL Liver enzymes [ ALT AST ] twice normal range Glomerular filtration rate &lt; 60 mL/min [ CockcroftGault ]</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>